Ischemia Modified Albumin levels in patients with Stable Angina Pectoris who underwent Percutaneous Coronary Intervention

  • Hariadi Hariawan Department of Cardiology, Medical Faculty Gajah Mada University, Dr. Sardjito General Hospital, Jogyakarta
  • Otte J Rachman Department of Cardiology and Vascular Medicine, Medical Faculty University of Indonesia National Cardiovascular Center, Harapan Kita, Jakarta
  • Yoga Yuniadi Department of Cardiology and Vascular Medicine, Medical Faculty University of Indonesia National Cardiovascular Center, Harapan Kita, Jakarta

Abstract

Background. Ischemia Modified Albumin (IMA) is a biomarker of myocardial ischemia. Blood levels of IMA rise in patients who develop ischemia during percutaneous coronary intervention (PCI). This study evaluated the relation between IMA levels and variables of procedure during coronary angioplasty such as number of balloon inflations, inflation pressure and duration of inflations in patients with stable angina pectoris who underwent PCI.
Methods and results. Twenty three consecutive patients (21 men and 2 women), range of age 41 to 80 years old with stable angina pectoris underwent elective PCI between March to April 2006. Blood samples were drawn from femoral or radial artery sheath 10 minutes before PCI and 10 minutes after the last balloon inflation for IMA levels measurement. IMA levels increased positive from 95.26+8.44U/mL before PCI to a level 135.07+18.80U/mL after PCI (p<0.0001). All of the patients used stents except in 2 cases. There are significant correlation between elevation of IMA levels with number of balloon inflation (r=0.59;p=0.003), total pressure inflation (r=0.48;p=0.02) and total duration of balloon inflation (r=0.48;p=0.02).
Conclusion. Ischemia Modified Albumin (IMA) levels significantly elevated after percutaneous coronary angioplasty (PCI). There were positive correlation between numbers of inflations, total pressure and total duration of balloon inflations.

Downloads

Download data is not yet available.

References

Wu, AHB. The ischemia-modified albumin biomarker for myo-cardial ischemia. Clinical issue. www.mlo-online.com. June 2003 p.38

Kantas MC, Jesse RL. Evaluation of the emergency department chest pain patient. Am J Cardiol2000;85:328-9B

Ishikawa Y,Saffitz JE, Mealman TL et al. Reversible myocardial ischemic injury is not associated with increased creatine kinase activity in plasma. Clin Chem1997;43:467-75.

Brogan GX, Hollander JE, Mc Curkey CF. Evaluation of a new assay for cardiac troponin I vs creatin kinase MB for the diagnosis of acute myocardial infarction. Acad Emerg Med1997;4: 6-12.

Hedges JR, Swanson JR, Hester C et al. Prospective assessment of presenting serum markers for cardiac risk stratification. Acad Emerg Med1996;3:27-33.

Bar DO, Winkler JV, Benthuysen KV et al. Reduced albumin-cobalt binding with transient myocardial ischemia after percu-taneous trans-luminal coronary angioplasty: A preliminary com-parison to creatine kinase-MB, myoglobin and troponin I. Am Heart JJune 2001:985-91.

Bertinchant JP, Polge A, Ledermann B et al. Relation of minor cardiac troponin I elevation to late cardiac events after uncompliated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. Am J Cardiol 1999:84:51-7.

Ravkilde J, Nissen H, Mickley H et al. Cardiac troponin I and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. Am Heart J1994;127:13-20.

Winter RD Ischemia from the Clinician Point’s of View. Inter-national Workshop on Ischemia,Barcelona Spain 2002: 11-12

Baxter GF Cellular Mechanism of Ischemic Myocard Damage. International Workshop on Ischemia, Barcelona Spain 2002: 5-9

Kaski JC Introduction to the Ischemia Workshop. International Workshop on IschemiaBarcelona Spain 2002;1-3

Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J2004,25:634-7

Christenson RH, Duh SH, Sanhai W, et al. Charasteristic of an Albumin Cobalt Binding Test for Assessment of Acute Coro-nary Syndrome Patients:A Multicenter Study. Clin Chem 2001;47:464-70.

Weilert M. Ishemia-Modified Albumin New Cardiac Marker California Association for Medical Laboratory Technology. Dis-tance Learning Program2003:2-4

Dellborg M, Emanuelsson H, Swedberg K. Silent myocardial ischemia during coronary angioplasty. Cardiolog y 1993; 82(5):325-34

Bar -Or D, Lau E, Winkler JV. A novel assay for cobalt-albu-min binding and its potential as a marker for myocardial is-chemia a preli-minary report. J Emerg Med2000:19:311-15

Bar Or D, Curi G, Rao N, et al. Characteriza-tion of the Co(2+) and Ni(2+) binding amino acid residues of the N-terminus of human abumin.. Eur J Biochem2001;268:42-7

Sabatine MS When prognosis precedes diagnosis: putting the cart before the horse CMAJ2005,172(13): 10

Sinha MK, Gaze DC, Tippins JR, et al. Ischemia Modified Al-bumin is a sensitive Marker of Myocardial Ischemia After PCI Circulation2003;107:2403-5

Christenson RH, Duh SH, Sanhai W, et.al. Charasteristic of an Albumin Cobalt Binding Test for Assessment of Acute Coro-nary Syndrome Patients: A Multicenter Study. Clin Chem 2001;47:464-70.

Marx G, Chevion M Site-specific modification of albumin by free radicals. Biochem J1985;236:397-400.

Quiles J, Roy D, Gaze D, Garrido IP, Avanzas P, Sinha M, Kaski CC Relation of Ischemia Modified Albumin Levels following Elective Angioplasty to Duration of Balloon-Induced Myocar-dial Ischemia Am J Cardiol2003;92: 322-4
Views & Downloads
Abstract views: 789   
PDF (Bahasa Indonesia) downloads: 527   
How to Cite
Hariawan, H., Rachman, O., & Yuniadi, Y. (1). Ischemia Modified Albumin levels in patients with Stable Angina Pectoris who underwent Percutaneous Coronary Intervention. Indonesian Journal of Cardiology, 28(1), 27-35. https://doi.org/10.30701/ijc.v28i1.264
Section
Clinical Research